Conivaptan
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Conivaptan: From Hyponatremia to Pulmonary Hypertension
One-Sentence Summary
Conivaptan (DB00872) is a dual V1A/V2 vasopressin receptor antagonist whose original clinical use — evident from the accompanying literature evidence — is management of euvolemic/hypervolemic hyponatremia in hospitalized patients (including congestive heart failure). The TxGNN model predicts it may be effective for Pulmonary Hypertension, but this direction is currently supported by only 1 withdrawn clinical trial (0 enrolled) and 1 review article, making the evidence base too thin to act on.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hyponatremia (per literature evidence; not confirmed via a local market license) |
| Predicted New Indication | Pulmonary Hypertension |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Formal mechanism-of-action documentation for conivaptan is currently a data gap. Based on the pharmacological context captured in this evidence pack’s repurposing rationale, conivaptan is understood to be a dual V1A/V2 vasopressin receptor antagonist: V1A blockade reduces systemic and pulmonary vascular resistance and afterload, while V2 blockade produces aquaresis (water diuresis without sodium loss).
The proposed link to pulmonary hypertension is indirect. Pulmonary arterial hypertension with right ventricular failure involves secondary hyperaldosteronism and non-osmotic arginine vasopressin release, driving sodium and water retention — the same physiological axis conivaptan’s dual antagonism targets. In theory, this could relieve volume overload and improve ventricular interdependence in PAH patients with right heart failure.
However, this remains a mechanistic hypothesis rather than a validated therapeutic pathway. The one clinical trial designed to test a closely related question (NCT00811486) was withdrawn before enrolling any patients, and the supporting literature discusses hyponatremia management in heart failure broadly rather than pulmonary hypertension specifically.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00811486 | N/A | Withdrawn | 0 | Designed to test whether mineralocorticoid antagonist (natriuretic) plus V2 receptor antagonist (aquaretic) doses could attenuate sodium and water retention in PAH with right ventricular failure; trial was withdrawn with no patients enrolled, so no data were generated. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30843491 | 2019 | Review | Current Cardiology Reviews | Reviews pathogenesis and management of hyponatremia in heart failure, distinguishing dilutional (hypervolemic) from hypovolemic mechanisms; does not directly address pulmonary hypertension. |
India Market Information
Currently no marketing authorization in India — conivaptan has 0 registered licenses and is classified as not marketed.
Safety Considerations
Drug Interactions: DDI screening identified 180 total interactions. Notable Major-severity interactions include Loperamide, Triamcinolone, Budesonide, Clarithromycin, Cisapride, Eliglustat, and Naloxegol. Moderate-severity interactions include Rabeprazole, Hydrocortisone (systemic and ophthalmic), Aprepitant, Dexamethasone (systemic, nasal, and ophthalmic), Betamethasone, Budesonide (nasal), Eluxadoline, Granisetron, Miconazole, and Naldemedine — consistent with conivaptan’s known strong CYP3A4 inhibition.
Detailed labeled warnings and contraindications are not yet available in this evidence pack; please refer to the package insert for that information once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: The only trial directly testing this mechanistic hypothesis in the target population was withdrawn without enrolling any patients, and no literature specifically evaluates conivaptan in pulmonary hypertension. Evidence level L4 (mechanism-only) does not support advancing beyond a research question at this time, and the drug is not currently marketed in India, adding a regulatory access gap.
To proceed, the following is needed:
- Confirmed mechanism-of-action documentation (currently a Blocking data gap per DG002)
- Package insert warnings/contraindications (Blocking data gap per DG001)
- A completed (non-withdrawn) clinical trial or preclinical PAH model data linking V1A/V2 antagonism to measurable pulmonary hemodynamic benefit
- Assessment of India market entry feasibility given zero current registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.